91 research outputs found
TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity
TL1A and its functional receptor DR3 are members of the TNF/TNFR superfamilies of proteins. Binding of APC-derived TL1A to lymphocytic DR3 provides co-stimulatory signals for activated lymphocytes. DR3 signaling affects the proliferative activity of and cytokine production by effector lymphocytes, but also critically influences the development and suppressive function of regulatory T-cells. DR3 was also found to be highly expressed by innate lymphoid cells (ILCS), which respond to stimulation by TL1A. Several recent studies with transgenic and knockout mice as well as neutralizing or agonistic antibodies for these two proteins, have clearly shown that TL1A/DR3 are important mediators of several chronic immunological disorders, including Inflammatory Bowel Disease (IBD). TL1A and DR3 are abundantly localized at inflamed intestinal areas of patients with IBD and mice with experimental ileitis or colitis and actively participate in the immunological pathways that underlie mucosal homeostasis and intestinal inflammation. DR3 signaling has demonstrated a dichotomous role in mucosal immunity. On the one hand, during acute mucosal injury it exerts protective functions by ameliorating the severity of acute inflammatory responses and facilitating tissue repair. On the other hand, it critically participates in the pro-inflammatory pathways that underlie chronic inflammatory responses, such as those that take place in IBD. These effects are mediated through modulation of the relative mucosal abundance and function of Th1, Th2, Th17, Th9, and Treg lymphocytes, but also of all types of ILCs. Recently, an important role was demonstrated for TL1A/DR3 as potential mediators of intestinal fibrosis that is associated with the presence of gut inflammation. These accumulating data have raised the possibility that TL1A/DR3 pathways may represent a valid therapeutic target for chronic immunological diseases. Nevertheless, applicability of such a therapeutic approach will greatly rely on the net result of TL1A/DR3 manipulation on the various cell populations that will be affected by this approach
Atypical Mycobacterial Infection Presenting as Persistent Skin Lesion in a Patient with Ulcerative Colitis
Immunosuppressive drugs are commonly used for the treatment of inflammatory bowel disease. Patients receiving immunosuppressants are susceptible to a variety of infections with opportunistic pathogens. We present a case of skin infection with Mycobacterium chelonae in a 60-year-old Caucasian woman with ulcerative colitis who had been treated with corticosteroids and azathioprine. The disease manifested with fever and rash involving the right leg. Infliximab was administered due to a presumptive diagnosis of pyoderma gangrenosum, leading to worsening of the clinical syndrome and admission to our hospital. Routine cultures from various sites were all negative. However, Ziehl-Neelsen staining of pus from the lesions revealed acid-fast bacilli, and culture yielded a rapidly growing mycobacterium further identified as M. chelonae. The patient responded to a clarithromycin-based regimen. Clinicians should be aware of skin lesions caused by atypical mycobacteria in immunocompromised patients with inflammatory bowel disease. Furthermore, they should be able to thoroughly investigate and promptly treat these conditions
Co-expression of fibrotic genes in inflammatory bowel disease; A localized event?
IntroductionExtracellular matrix turnover, a ubiquitous dynamic biological process, can be diverted to fibrosis. The latter can affect the intestine as a serious complication of Inflammatory Bowel Diseases (IBD) and is resistant to current pharmacological interventions. It embosses the need for out-of-the-box approaches to identify and target molecular mechanisms of fibrosis.Methods and resultsIn this study, a novel mRNA sequencing dataset of 22 pairs of intestinal biopsies from the terminal ileum (TI) and the sigmoid of 7 patients with Crohn’s disease, 6 with ulcerative colitis and 9 control individuals (CI) served as a validation cohort of a core fibrotic transcriptomic signature (FIBSig), This signature, which was identified in publicly available data (839 samples from patients and healthy individuals) of 5 fibrotic disorders affecting different organs (GI tract, lung, skin, liver, kidney), encompasses 241 genes and the functional pathways which derive from their interactome. These genes were used in further bioinformatics co-expression analyses to elucidate the site-specific molecular background of intestinal fibrosis highlighting their involvement, particularly in the terminal ileum. We also confirmed different transcriptomic profiles of the sigmoid and terminal ileum in our validation cohort. Combining the results of these analyses we highlight 21 core hub genes within a larger single co-expression module, highly enriched in the terminal ileum of CD patients. Further pathway analysis revealed known and novel inflammation-regulated, fibrogenic pathways operating in the TI, such as IL-13 signaling and pyroptosis, respectively.DiscussionThese findings provide a rationale for the increased incidence of fibrosis at the terminal ileum of CD patients and highlight operating pathways in intestinal fibrosis for future evaluation with mechanistic and translational studies
Patients with inflammatory bowel disease are not at increased risk of COVID-19 : a large multinational cohort study
The impact of COVID-19 on inflammatory bowel disease (IBD) patients under pharmacological
immunosuppression is still not clearly understood. We investigated the incidence of COVID-19 and
the impact of immunosuppression and containment measures on the risk of SARS-CoV-2 infection in a
large IBD cohort, from a multicenter cohort from 21st of February to 30th of June, 2020. Ninety-seven
patients with IBD (43 UC, 53 CD, one unclassified IBD) and concomitant COVID-19 over a total
of 23,879 patients with IBD were enrolled in the study. The cumulative incidence of SARS-CoV-2 infection in patients with IBD vs. the general population was 0.406% and 0.402% cases, respectively.
Twenty-three patients (24%) were hospitalized, 21 (22%) had pneumonia, four (4%) were admitted to
the Intensive Care Unit, and one patient died. Lethality in our cohort was 1% compared to 9% in the
general population. At multivariable analysis, age > 65 years was associated with increased risk of
pneumonia and hospitalization (OR 11.6, 95% CI 2.18–62.60; OR 5.1, 95% CI 1.10–23.86, respectively),
treatment with corticosteroids increased the risk of hospitalization (OR 7.6, 95% CI 1.48–40.05),
whereas monoclonal antibodies were associated with reduced risk of pneumonia and hospitalization
(OR 0.1, 95% CI 0.04–0.52; OR 0.3, 95% CI 0.10–0.90, respectively). The risk of COVID-19 in patients
with IBD is similar to the general population. National lockdown was effective in preventing infection
in our cohort. Advanced age and treatment with corticosteroids impacted negatively on the outcome
of COVID-19, whereas monoclonal antibodies did not seem to have a detrimental effect.peer-reviewe
Exploring the Early Phase of Crohn's Disease
The development of Crohn's disease (CD) is characterized by a breakdown
of homeostatic immune-bacterial communication, which takes place at the
intestinal mucosa when environmental triggers impact genetically
predisposed individuals. Converging lines of evidence support the
hypothesis that this pathogenetic model develops through sequential,
although inter-related, steps that indicate failure of mucosal defense
mechanisms at various stages. In this context, immunologic phenomena
that mediate the initial appearance of inflammatory lesions across the
intestinal tissue may differ substantially from those that mediate and
perpetuate chronic inflammatory responses. A compromise in the integrity
of the epithelial barrier is among the earliest events and leads to
accelerated influx of intraluminal antigens and intact microorganisms
within the immunologically rich lamina propria. Inadequate clearance of
invading microorganisms also may occur as a result of defects in innate
immunity, preventing the timely and complete resolution of acute
inflammatory responses. The final step is the development of persistent
adaptive responses, which also differ between early and late Crohn's
disease. Current progress in our ability to delineate single-cell
transcriptomics and proteomics has allowed the discovery of cellular and
molecular mechanisms that participate in each sequential step of CD
development. This not only will advance our understanding of CD
pathogenesis, but also facilitate the design of targeted therapeutic
approaches
Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn’s Disease Patients
Background and Aim. Crohn’s disease (CD) is a chronic inflammatory condition of the gastrointestinal tract with the potential to progress to a severe debilitating state. Treatment with biological agents is highly efficient, improving both short-term outcomes and long-term prognosis. Nonetheless, up to 60% of patients receiving biological therapy will exhibit nonresponse at some point. The optimal management of such patients is not clearly defined. Besides traditional anti-TNF agents (infliximab, adalimumab, and certolizumab), alternative biological therapies (natalizumab, vedolizumab, and ustekinumab) are currently available for the treatment of CD. Our aim was to analyze all available evidence regarding efficacy of a second biological in “biological-treatment-experienced” patients. Methods. A systematic review of the literature was conducted using specific criteria for selecting relevant randomized clinical trials evaluating response to administration of secondary biological therapy in “anti-TNF-experienced” CD patients. Data from these studies was used to perform (a) traditional meta-analysis to ascertain the effect of secondary treatment versus placebo and (b) network meta-analysis to compare indirectly the efficacy of available biological agents. Results. Out of initially 977 studies, only eight were included for analysis, providing a total of 1281 treated and 733 placebo-receiving CD patients. Treatment with a second biological was found to be superior to placebo for both induction of remission (OR 2.2, 95% CI 1.7 to 3) and response (OR 1.9, 95% CI 1.5 to 2.5), with global rates of 24% and 42%, respectively (placebo rate: 11% and 27%, p<0.0001 for both). Indirect comparisons performed with network meta-analysis suggest no specific agent is clearly superior to others, with relatively better results observed for adalimumab in inducing disease remission. Conclusion. In anti-TNF-experienced CD patients, secondary biological administration may be efficient, while no specific agent seems to outperform the others. Further research is needed to identify optimal management strategies for this challenging subset of patients
Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn's Disease Patients
Background and Aim. Crohn’s disease (CD) is a chronic inflammatory
condition of the gastrointestinal tract with the potential to progress
to a severe debilitating state. Treatment with biological agents is
highly efficient, improving both short-term outcomes and long-term
prognosis. Nonetheless, up to 60% of patients receiving biological
therapy will exhibit nonresponse at some point. The optimal management
of such patients is not clearly defined. Besides traditional anti-TNF
agents (infliximab, adalimumab, and certolizumab), alternative
biological therapies (natalizumab, vedolizumab, and ustekinumab) are
currently available for the treatment of CD. Our aim was to analyze all
available evidence regarding efficacy of a second biological in
“biological-treatment-experienced” patients. Methods. A systematic
review of the literature was conducted using specific criteria for
selecting relevant randomized clinical trials evaluating response to
administration of secondary biological therapy in
“anti-TNF-experienced” CD patients. Data from these studies was used
to perform (a) traditional meta-analysis to ascertain the effect of
secondary treatment versus placebo and (b) network meta-analysis to
compare indirectly the efficacy of available biological agents. Results.
Out of initially 977 studies, only eight were included for analysis,
providing a total of 1281 treated and 733 placebo-receiving CD patients.
Treatment with a second biological was found to be superior to placebo
for both induction of remission (OR 2.2, 95% CI 1.7 to 3) and response
(OR 1.9, 95% CI 1.5 to 2.5), with global rates of 24% and 42%,
respectively (placebo rate: 11% and 27%, p < 0 0001 for both).
Indirect comparisons performed with network meta-analysis suggest no
specific agent is clearly superior to others, with relatively better
results observed for adalimumab in inducing disease remission.
Conclusion. In anti-TNF-experienced CD patients, secondary biological
administration may be efficient, while no specific agent seems to
outperform the others. Further research is needed to identify optimal
management strategies for this challenging subset of patients
- …